Development of ellagic acid-derived bismuth MOF for targeted therapy in colitis.
Saved in:
| Title: | Development of ellagic acid-derived bismuth MOF for targeted therapy in colitis. |
|---|---|
| Authors: | Wang Y; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China., Huang X; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China., Luo X; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China., He M; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China., Fang Y; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China., Yang D; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. Electronic address: dongzhiy@xzhmu.edu.cn. |
| Source: | Biomaterials advances [Biomater Adv] 2026 Apr; Vol. 181, pp. 214646. Date of Electronic Publication: 2025 Dec 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 9918383886206676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2772-9508 (Electronic) Linking ISSN: 27729508 NLM ISO Abbreviation: Biomater Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
